Catheter and implants for the delivery of therapeutic agents to tissues

• US 6,749,617 B1
• Filed: 11/08/2000
• Issued: 06/15/2004
• Est. Priority Date: 11/04/1997
• Status: Expired due to Term

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Scimed Life Systems Incorporated (Boston Scientific Corporation)
• Inventors: Barry, James J., Palasis, Maria
• Primary Examiner(s): WORRELL JR, LARRY D
• Application Number:
  US09/709,031
• Time in Patent Office: 1,315 Days
• Field of Search: 606/167, 606/185, 606/181, 606/184, 606/171, 606/41, 606/45, 128/898
• US Class Current: 606/181
• CPC Class Codes: A61B 17/3468 for implanting or removing devices, e.g. prostheses, implants, seeds, wires devices for implanting seeds A61M37/0069
• CPC Class Codes: A61B 17/3478 Endoscopic needles, e.g. for infusion biopsy needles A61B10/0233; catheters with injection needles A61M25/0067
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/320084 Irrigation sleeves
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61B 2018/1425 Needle
• CPC Class Codes: A61B 90/39 Markers, e.g. radio-opaque or breast lesions markers
• CPC Class Codes: A61F 2/2493 Transmyocardial revascularisation [TMR] devices
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61M 2025/0004 having two or more concentrically arranged tubes for forming a concentric catheter system
• CPC Class Codes: A61M 2025/0089 Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
• CPC Class Codes: A61M 25/0084 being one or more injection needles
• CPC Class Codes: A61M 37/0069 Devices for implanting pellets, e.g. markers or solid medicaments for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027

Abstract

A catheter is provided for delivering implants including therapeutic agents to tissues. The catheter is advanceable intra-luminally to place the implants. In one embodiment, the implants include a liquid carrier and therapeutic agent for infusion into the tissue. In another embodiment, a solid carrier includes the therapeutic agent. In yet another embodiment, the implant is formed in situ.

Claims

1. A therapeutic implant system, comprising:

an elongate catheter having a distal end including a lumen, and

a therapeutic carrier disposed within the lumen, the carrier adapted to allow therapeutic to be released to a target site from the carrier after the carrier has been deployed from the catheter at the target site, the carrier having a solid form at least after it is deployed from the catheter.

2. The system in accordance with claim 1, wherein the carrier is bio-stable.

3. The system in accordance with claim 1, wherein the carrier is biodegradable.

4. The system in accordance with claim 1, wherein the therapeutic agent is selected from the agents consisting of VEGF, FGF, PDGF, estrogen and combinations thereof.

5. The system in accordance with claim 1, wherein the therapeutic agent includes genes effecting the production of growth factors.

6. The system in accordance with claim 1, wherein the therapeutic agent includes genetically engineered cells.

7. The system in accordance with claim 1, wherein the therapeutic agent includes healthy tissue.

8. The system in accordance with claim 1, wherein the therapeutic agents are selected from the agents consisting of positive inotripic, diuretics vasodilators, nuerohormonal antagonists, calcium, channel blockers, anti-ischemic agents, anti-arrhythmics, anticoagulants, natiruretic peptides, growth hormones, and adenosine receptor antagonists and mixtures thereof.

9. The system in accordance with claim 1, wherein the therapeutic agents are selected from the agents consisting of AKT kinases, adenylyl cylase VI, angiogenisis inducing agents and mixtures thereof.

10. The system in accordance with claim 1, wherein the therapeutic agents are selected from the agents comprising cytoxic proteins, cytostatic agents, genes, anti-angiogenic molecules and mixtures thereof.

11. The system in accordance with claim 1, wherein the catheter includes a first lumen and a second lumen.

12. The system in accordance with claim 11, wherein an exit orifice of the second lumen is positioned within the first lumen.

13. The system in accordance with claim 12 wherein the first lumen and the second lumen share a longitudinal axis.

14. The system in accordance with claim 13 wherein the first lumen is concentric with the second lumen.

15. The system in accordance with claim 11 wherein the carrier is in the first lumen and a therapeutic is in the second lumen.

16. The system in accordance with claim 1 wherein the lumen contains a radiopaque material.

17. The system in accordance with claim 11 wherein the first lumen contains a polymer cross-linking agent and the second lumen contains a polymer.